SGX Pharmaceuticals Inc (SGXP)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

10505 ROSELLE STREET SAN DIEGO, CA 92121

SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of cancer therapeutics. It is developing an internal oncology product pipeline and lead compounds through the application of its proprietary drug discovery platform, Fragments of Active Structures (FAST). The company's pre-clinical development programs include BCR-ABL Kinase Inhibitor Program that focuses on compounds, which inhibit wild-type and Gleevec-resistant mutant forms of BCR-ABL tyrosine kinase, the enzyme that is responsible for CML; and MET Tyrosine Kinase Receptor Inhibitor program that inhibits solid tumors. In addition, it develops JAK2, a non-receptor tyrosine kinase protein; and RAS that is in the lead identification stage, which regulates cell growth. The company has collaboration and license agreements with Novartis Institutes for Biomedical Research, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; National Institutes of Health; and Eli Lilly & Company.

View SEC Filings from SGXP instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SGXP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SGXP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MYERS W TODD CFO

  • Officer
No longer subject to file 2008-08-20 0

REICH SIEGFRIED VP, DRUG DISCOVERY

  • Officer
No longer subject to file 2008-08-20 0

GREY MICHAEL G PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2008-08-20 0

BURLEY STEPHEN CSO & SVP, RESEARCH

  • Officer
No longer subject to file 2008-08-20 0

NORTH ANNETTE GENERAL COUNSEL

  • Officer
No longer subject to file 2008-08-20 0

RUGG TERENCE ANTHONY CMO & VP, DRUG DEVELOPMENT

  • Officer
No longer subject to file 2008-08-20 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
No longer subject to file 2008-08-20 0

EASTHAM KARIN

  • Director
No longer subject to file 2008-08-20 0

TURNER JOSEPH L

  • Director
No longer subject to file 2008-08-20 0

HENNEY CHRISTOPHER S

  • Director
No longer subject to file 2008-08-20 0

BOCK LOUIS C

  • Director
  • 10% Owner
No longer subject to file 2008-08-20 0

BAVP, L.P.

  • 10% Owner
No longer subject to file 2008-08-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments